Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer-Reference-Cited by-同舟云学术

Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer

Published:2016-12-01 Issue:12 Volume:2 Page:1557
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Awada Ahmad¹,Colomer Ramon²,Inoue Kenichi³,Bondarenko Igor⁴,Badwe Rajendra A.⁵,Demetriou Georgia⁶,Lee Soo-Chin⁷,Mehta Ajay O.⁸,Kim Sung-Bae⁹,Bachelot Thomas¹⁰,Goswami Chanchal¹¹,Deo Suryanarayan¹²,Bose Ron¹³,Wong Alvin¹⁴,Xu Feng¹⁴,Yao Bin¹⁴,Bryce Richard¹⁴,Carey Lisa A.¹⁵

Affiliation:

1. Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Bruxelles, Belgium

2. Division of Medical Oncology, Hospital Universitario La Princesa, Madrid, Spain

3. Division of Breast Oncology, Saitama Cancer Center, Ina, Japan

4. Dnepropetrovsk State Medical Academy, Dnepropetrovsk, Ukraine

5. Tata Memorial Centre, Parel, India

6. University of the Witwatersrand Department of Medical Oncology and Wits Donald Gordon Medical Centre, Johannesburg, South Africa

7. National University Cancer Institute, Singapore, Singapore

8. Central India Cancer Research Institute, Nagpur, India

9. Asan Medical Center, University of Ulsan, Seoul, South Korea

10. Centre Léon Bérard, Lyon, France

11. B.P. Poddar Hospital and Medical Research Ltd, Kolkata, India

12. Institute Rotary Cancer Hospital, AIIMS, New Delhi, India

13. Washington University School of Medicine, St Louis, Missouri

14. Puma Biotechnology Inc, Los Angeles, California

15. Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 252 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy;European Journal of Medicinal Chemistry;2024-10

2. Pharmacotherapy for cervical cancer: current standard of care and new perspectives;Expert Opinion on Pharmacotherapy;2024-08-12

3. Preclinical and clinical evaluation through serial colonoscopic evaluation of neratinib‐induced diarrhea in HER2‐positive breast cancer—A pilot study;Physiological Reports;2024-08

4. Trastuzumab-Induced Cardiotoxicity: When and How Much Should We Worry?;JCO Oncology Practice;2024-08

5. Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer;Cancers;2024-07-24